ReviewRadiation oncology (London, England)2018
PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives.
Abstract readReview
In one paragraph
Review in Radiation oncology (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Radiotherapy of oligometastatic prostate cancer: a systematic review.Radiation oncology (London, England) · 2021Pooled it
- Pelvic lymph node mapping in prostate cancer: examining the impact of PSMA PET/CT on radiotherapy decision-making in patients with node-positive disease.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Article
- The Current Landscape of Prostate-Specific Membrane Antigen (PSMA) Imaging Biomarkers for Aggressive Prostate Cancer.Cancers · 2024Review
- [Opportunities for prostate-specific membrane antigen hybrid imaging in prostate cancer].Urologie (Heidelberg, Germany) · 2023Review
- Radiotherapy treatment modification for prostate cancer patients based on PSMA-PET/CT.Radiation oncology (London, England) · 2022Article
- Urethra Sparing With Target Motion Mitigation in Dose-Escalated Extreme Hypofractionated Prostate Cancer Radiotherapy: 7-Year Results From a Phase II Study.Frontiers in oncology · 2022Article
- Health-related quality of life of salvage prostate reirradiation using stereotactic ablative radiotherapy with urethral-sparing.Frontiers in oncology · 2022Article
- Intraindividual comparison of [EJNMMI research · 2021Article
- A survey among German-speaking radiation oncologists on PET-based radiotherapy of prostate cancer.Radiation oncology (London, England) · 2021Article
- Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Review
- Androgen Receptor Targeted Therapy + Radiotherapy in Metastatic Castration Resistant Prostate Cancer.Frontiers in oncology · 2021Article
- Local failure after definitive radiation treatment of lymph-node positive prostate cancer: supporting the use of novel imaging techniques to personalize treatment options.BJR case reports · 2020Article
- Image guidance in radiation therapy for better cure of cancer.Molecular oncology · 2020Review
- Preclinical Dosimetry, Imaging, and Targeted Radionuclide Therapy Studies of Lu-177-Labeled Albumin-Binding, PSMA-Targeted CTT1403.Molecular imaging and biology · 2020Article
- Expanding the role of small-molecule PSMA ligands beyond PET staging of prostate cancer.Nature reviews. Urology · 2020Review
- Comparison of Manual and Semi-Automatic [Frontiers in oncology · 2020Article
- New metabolic tracers for detectable PSA levels in the post-prostatectomy setting: is the era of melting glaciers upcoming?Translational andrology and urology · 2019Article
- Impact ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019Article
- MR-guidance in clinical reality: current treatment challenges and future perspectives.Radiation oncology (London, England) · 2019Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Sebastian ZschaeckDepartment of Radiation Oncology, Klinik für Radioonkologie und Strahlentherapie, Charité Universitätsmedizin Berlin, Berlin, Germany. Sebastian.Zschaeck@charite.de.ORCID http://orcid.org/0000-0003-3109-0662
Fabian LohausDepartment of Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Marcus BeckDepartment of Radiation Oncology, Klinik für Radioonkologie und Strahlentherapie, Charité Universitätsmedizin Berlin, Berlin, Germany.
Gregor HablDepartment of Radiation Oncology, Technical University of Munich (TUM), Munich, Germany.
Stephanie KroezeDepartment of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland.
Constantinos ZamboglouDepartment of Radiation Oncology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Dresden, Germany.
Stefan Alexander KoerberDepartment of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.
Jürgen DebusDepartment of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.
Tobias HölscherDepartment of Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Peter WustDepartment of Radiation Oncology, Klinik für Radioonkologie und Strahlentherapie, Charité Universitätsmedizin Berlin, Berlin, Germany.
Ute GanswindtDepartment of Therapeutic Radiology and Oncology, Innsbruck Medical University, Innsbruck, Austria.
Alexander D J BaurDepartment of of Radiology, Universitätsmedizin Berlin, Berlin, Germany.
Klaus ZöphelNuclear Medicine Department, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.
Nikola CihoricDepartment of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, München, Switzerland.
Matthias GuckenbergerDepartment of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland.
Stephanie E CombsDepartment of Radiation Oncology, Technical University of Munich (TUM), Munich, Germany.
Anca Ligia GrosuDepartment of Radiation Oncology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Dresden, Germany.
Pirus GhadjarDepartment of Radiation Oncology, Klinik für Radioonkologie und Strahlentherapie, Charité Universitätsmedizin Berlin, Berlin, Germany.
Claus BelkaDepartment of Radiation Oncology, Ludwig-Maximilians-University, Munich, Germany.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Antigens, SurfaceGlutamate Carboxypeptidase IIHumansMalePositron-Emission TomographyPractice Patterns, Physicians'Prostatic NeoplasmsRadiopharmaceuticalsSurveys and QuestionnairesAntigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase IIRadiopharmaceuticalsImage guided treatment planningPrimary radiotherapyProstate-cancerPSMA-PETReviewSalvage radiotherapySurvey
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.